$7.16
▼ -0.3% Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update
Overview
52-week range
$3.65
$11
48% of range
Avg surprise (last 3)
+11.7%
Avg reaction (last 2)
+1.4%
100% positive
Latest IV / EM
264%
EM ±60.4% · $8 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-1.24 | $-1.45 | +14.5% | +55.2% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-3.82 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-4.32 | $-3.80 | -13.7% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-2.77 | $-4.21 | +34.2% | — | +2.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.85 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.97 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-4.85 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.30 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.29 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$1.25 | -$4.32 | +71.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | — | $44M | $38M | $30M | — | $39M | $43M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | — | $-15M | $-24M | $-33M | — | $-26M | $-28M |
| Net income | $-22M | — | $-33M | $-37M | $-23M | — | $-32M | $24M |
| EPS (diluted) | $-1.24 | — | $-3.82 | $-4.32 | $-2.77 | — | $-3.85 | $-2.97 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $91M | $61M | $38M | $39M | $39M | $62M | $73M | $85M |
| Inventory | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $3M |
| Total current assets | $126M | $103M | $90M | $98M | $120M | $156M | $185M | $209M |
| Total assets | $131M | $108M | $96M | $105M | $128M | $164M | $189M | $214M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $397M | $401M | $365M | $344M | $334M | $350M | $349M | $346M |
| Total equity | $-266M | $-293M | $-269M | $-239M | $-206M | $-186M | $-160M | $-132M |